Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

fda Press Releases

  + XML/RSS  



By Olympia Pharmacy
Olympia Compounding Pharmacy announced today it has voluntarily registered with the FDA as an outsourcing facility.

By SEMDA
Southeastern Medical Device Association (SEMDA) Addressing Reform Impact Head-on

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces the FDA SBA BLA Fee Waiver has been Granted & Clears a Path for the REMUNE HIV/AIDS Vaccine Approval

By Medicast Inc. And Expect Advertising, Inc.
“Continued use of non-approved drugs when a safe, FDA-approved product is available is not in the public interest and can lead to legal lawsuits.” — Cindy Ippoliti, Pharm.D., NYP/Weill Cornell

By Public Interest Law Professor John Banzhaf
A federal appeals court has ruled that law suits against food companies for misrepresentation are not preempted by federal law, opening the door even further to a growing wave of such suits,

By Public Interest Law Professor John Banzhaf
Many states - just now Missouri - are in danger of having their scheduled executions delayed or even stopped by law suits over the drugs to be injected, but there appears to be a simple remedy which avoids virtually all of the problems

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.

By FDAnews
Device Supplier Controls: Does the FDA’s Next 483 Have Your Name on It? **FDAnews Virtual Conference** Feb. 26, 2014 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/SupplierControlsVCPR1

By Alliance for Natural Health USA
Sammy Hagar, Sen. Kelly Ayotte & 100,000 concerned citizens plead for agency to grant ‘Compassionate Use Exemption’

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship Vaccine NeuroVax Granted Orphan Designation for Pediatric MS by the FDA.

By The Cornucopia Institute
On December 11, 2013 the U.S. Food & Drug Administration (FDA) released a guidance document that asks animal-drug makers to voluntarily discontinue marketing antibiotics to farmers for faster livestock growth, limiting their use strictly to therapeutic...

By Mary Ann Liebert, Inc., publishers
The U.S. Food and Drug Administration (FDA) mandates adequate enrollment of women in post-approval studies (PAS) of medical devices to ensure that any sex differences in device safety and effectiveness are not overlooked.

By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.

By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.

By FDAnews
Leverage New Tools for Device CAPA Compliance **FDAnews Virtual Conference** Dec. 19, 2013 — 10:00 a.m. – 4:00 p.m.

By Immune Response BioPharma
Immune Response BioPharma to File Remune BLA with FDA by March 1st 2014 & Submits Fee Waiver Request, IRBP also plans to Transition the Vaccine to Preventative Use.

By Immune Response BioPharma, Inc.
Immune Response BioPharma to Keep U.S. NeuroVax Rights for MS Expects Phase IIb Enrollment to Begin by Q2 2015.

By FDAnews
Ensuring Market Success Via Environmental Compliance: How RoHS and REACH Could Hamper Your EU Sales **FDAnews FREE Webinar** Nov. 20, 2013 — 1:30 p.m. – 3:00 p.m. EST www.fdanews.com/MarketSuccessPR1

By A.D. Allen
Research scientist publishes a review of a public health crisis in online journal ADVANCES IN AGING RESEARCH.

By FDAnews
The FDA Unique Device Identification (UDI) Rule It’s Ready for You, Are You Ready for It? **FDAnews Virtual Conference** Nov. 19, 2013 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/UDIVirtualPR1

All Press Releases

By Professor John Banzhaf, GWU Law School
WASHINGTON, D.C. (April 14, 2014): Leaked documents indicate that electronic cigarettes, also known as e-cigarettes, may be zapped by the World Health Organization [WHO]

By Olympia Pharmacy
Olympia Compounding Pharmacy announced today it has voluntarily registered with the FDA as an outsourcing facility.

By SEMDA
Southeastern Medical Device Association (SEMDA) Addressing Reform Impact Head-on

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces the FDA SBA BLA Fee Waiver has been Granted & Clears a Path for the REMUNE HIV/AIDS Vaccine Approval

By Aging in Motion
Experts from the FDA and Science, Industry and Advocacy Groups Discuss Strategies to Advance Treatment for Condition

By GlobalSubmit
Software Release Includes New Module 1 Specifications, Performance Enhancements

By Medicast Inc. And Expect Advertising, Inc.
“Continued use of non-approved drugs when a safe, FDA-approved product is available is not in the public interest and can lead to legal lawsuits.” — Cindy Ippoliti, Pharm.D., NYP/Weill Cornell

By Public Interest Law Professor John Banzhaf
A federal appeals court has ruled that law suits against food companies for misrepresentation are not preempted by federal law, opening the door even further to a growing wave of such suits,

By Public Interest Law Professor John Banzhaf
Many states - just now Missouri - are in danger of having their scheduled executions delayed or even stopped by law suits over the drugs to be injected, but there appears to be a simple remedy which avoids virtually all of the problems

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.

By Farm Plus Financial Farm Loans
According to Farm Plus Financial Farm Loans at http://www.farmloans.com, the Food and Drug Administration recently took the first steps in banning the non-treatment-based use of antibiotics in US livestock, arguing that antibiotic abuse can lead to the...

By FDAnews
Device Supplier Controls: Does the FDA’s Next 483 Have Your Name on It? **FDAnews Virtual Conference** Feb. 26, 2014 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/SupplierControlsVCPR1

By Alliance for Natural Health USA
Sammy Hagar, Sen. Kelly Ayotte & 100,000 concerned citizens plead for agency to grant ‘Compassionate Use Exemption’

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship Vaccine NeuroVax Granted Orphan Designation for Pediatric MS by the FDA.

By The Cornucopia Institute
On December 11, 2013 the U.S. Food & Drug Administration (FDA) released a guidance document that asks animal-drug makers to voluntarily discontinue marketing antibiotics to farmers for faster livestock growth, limiting their use strictly to therapeutic...

By Mary Ann Liebert, Inc., publishers
The U.S. Food and Drug Administration (FDA) mandates adequate enrollment of women in post-approval studies (PAS) of medical devices to ensure that any sex differences in device safety and effectiveness are not overlooked.

By Immunotech Laboratories Inc.
Immunotech laboratories (immb) is pleased to announce that the financials for auditing have been completed and are now in the process of being audited.

By Professor John Banzhaf, GWU Law School
Nicotine, the substance to which bystanders are exposed when e-cigarettes are used, are a key contributing factor in the almost 50,000 annual nonsmoker deaths from secondhand tobacco smoke - and bystanders deserve to be protected

By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.

By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.

By Public Interest Law Professor John Banzhaf
Simple Regulations Cost Nothing, and Are Much More Efficient

By Better Shea Butter
Better Shea Butter has recently launched a new zinc oxide powder that offers customers excellent value for money.

By FDAnews
Leverage New Tools for Device CAPA Compliance **FDAnews Virtual Conference** Dec. 19, 2013 — 10:00 a.m. – 4:00 p.m.

By Immune Response BioPharma
Immune Response BioPharma to File Remune BLA with FDA by March 1st 2014 & Submits Fee Waiver Request, IRBP also plans to Transition the Vaccine to Preventative Use.

By Immune Response BioPharma, Inc.
Immune Response BioPharma to Keep U.S. NeuroVax Rights for MS Expects Phase IIb Enrollment to Begin by Q2 2015.

By FDAnews
Ensuring Market Success Via Environmental Compliance: How RoHS and REACH Could Hamper Your EU Sales **FDAnews FREE Webinar** Nov. 20, 2013 — 1:30 p.m. – 3:00 p.m. EST www.fdanews.com/MarketSuccessPR1

By A.D. Allen
Research scientist publishes a review of a public health crisis in online journal ADVANCES IN AGING RESEARCH.

By FDAnews
The FDA Unique Device Identification (UDI) Rule It’s Ready for You, Are You Ready for It? **FDAnews Virtual Conference** Nov. 19, 2013 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/UDIVirtualPR1

By SMi Group
SMi is delighted to announce that the former MHRA GMP Inspector, Di Morris, who is now consulting for Pharmaceutical Solutions Ltd, will be making a keynote address at SMi’s 3rd annual conference on Pharmaceutical Microbiology.

By Kemwell Biopharma
Cirrus Pharmaceuticals, Inc., NC, USA, a wholly owned subsidiary of Kemwell Biopharma Pvt. Ltd., announced that it was awarded a grant by the U.S.

By FDAnews
Medical Device Risk Management Beyond FMEA —New Tools to Assure Your Risk Management Program Meets New Standards **Presented by Ombu Enterprises and FDAnews** Nov. 5-6, 2013 — Chicago, IL www.fdanews.com/MDRiskPR1

By FDAnews
Cybersecurity Threats to Medical Devices Crush the Hackers Before They Crush You **FDAnews Webinar** Oct. 18, 2013 — 1:30 p.m. – 3:00 p.m. EDT www.fdanews.com/CybersecurityPR1

By Groff-Hinman
Recent FDA Approval Spurs Pent-Up Demand Among Middle Aged For New Eyelift Procedure

By FDAnews
Pay-to-Delay Settlements in the Wake of Activis Current, Former FTC Officials Offer Answers **FDAnews Virtual Conference** Oct. 15, 2013 — 10:00 a.m. – 12:30 p.m. EDT www.fdanews.com/PayToDelayPR1

By FDAnews
Is it an application or a device? The FDA breaks new ground.

By Mary Ann Liebert, Inc., publishers
Regulatory reform is needed to protect consumers from caffeine-induced harm and to help them make wise dietary choices, say the authors of an article in Journal of Caffeine Research.

By FDAnews
Eighth Annual FDA Inspections Summit New Powers, New Enforcement Posture, New Challenges **Presented by FDAnews** Oct. 23-25, 2013 – Bethesda, MD www.fdanews.com/FDAInspectionsSummitPR1

By smi group
Diabetes drug sales soared to a worldwide value of $34.1 billion in 2012, a compound annual growth rate of 10% since 2007.

By FDAnews
FDA Import Holds New Powers to Control Products **FDAnews Virtual Conference** Sept. 24, 2013 — 10:00 a.m. – 4:00 p.m. EDT www.fdanews.com/ImportHoldsVCPR1

By Labcompliance
This seminar will discuss how to effectively implement GMP regulations in quality control laboratories for FDA and EMA compliance.

By Labcompliance
This seminar will discuss how to use modern lifecycle management and quality by design principles to ensure method robustness for easy transfer and to avoid OOS situations

By Labcompliance
This seminar will give an overview on ICH Q3D and USP approaches to specify and control elemental impurities to below toxic limits in drug products and ingredients. The seminar will discuss in detail selected elements, limits and analytical procedure

By FDAnews
Eighth Annual FDA Inspections Summit New Powers, New Enforcement Posture, New Challenges **Presented by FDAnews** Oct. 23-25, 2013 – Bethesda, MD www.fdanews.com/FDAInspectionsPR1

By RnRMarketResearch.com
RnR Market Research adds new report on “PharmaFocus Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria” in its database.

By Ephedra Warehouse
Safety First – Beta Labs Reformulates Products for Consumers   Las Vegas, NV — Safety comes first at Beta Labs, Ltd. This supplement company strives to deliver high quality weight loss products to its consumers.   Products from Beta Labs, Ltd.

By CluePoints
CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced that its CSM techniques, that have been developed to improve data quality in studies, have been cited by the FDA in the recent release.

By FDAnews
Is It a Cosmetic, a Drug or Both? 15-Year Regulatory Veteran Shares Compliance Secrets **Presented by FDAnews** Aug. 23, 2013 • 1:30 p.m. – 3:00 p.m.

By Chiral Quest
  First USDMF Filed by Chiral Quest.   Suzhou, Jiangsu, PR China.  April 15th, 2013.

By Lean Compliance Partners LLC
Learn about FDA QSR, cGMP, GMP. Learn how FDA guidelines apply to medical device manufacturing and product quality. Identify gaps in quality system. Immediately apply learnings in your workplace. Hand on, live instructor training.

By Conversational Content, LLC
Healthy Food and Lifestyle Brand Applauds the Clear Guidelines



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share